权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Evaluating the decriminalization of non-prescribed buprenorphine in Rhode Island

评估罗德岛州非处方丁丙诺啡的非刑事化

基本信息

批准号：
10549069
负责人：
JOSIAH D RICH
金额：
$ 25.02万
依托单位：
RHODE ISLAND HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2022
资助国家：
美国
起止时间：
2022-08-15 至 2024-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10549069
关键词：
Accounting Affect Agonist Area Attitude Behavior Belief Benzodiazepines Buprenorphine Cessation of life Communities Companions Consumption Criminal Law Data Disincentive Drug Addiction Drug Controls Effectiveness Enrollment Evaluation Event FDA approved Fentanyl Frequencies Goals Harm Reduction Health Health Benefit Health Services Accessibility Heroin Illicit Drugs Interruption Intervention Interview Joints Justice Knowledge Law Enforcement Laws Measures Medicine Methadone Motivation Municipalities Narcotics National Institute of Drug Abuse New York Opioid Opioid agonist Outcome Overdose Overdose reduction Pattern Perception Personal Autonomy Persons Pharmaceutical Preparations Play Police Policies Population Protocols documentation Public Health Publications Recording of previous events Records Recreation Relapse Reporting Research Research Personnel Research Priority Rhode Island Risk Role Safety Science Self Medication Statutes and Laws Stigmatization Structure Substance Use Disorder System Text Time Time Series Analysis Toxicology Training Uncertain Risk Vermont Withdrawal addiction base buprenorphine treatment coronavirus disease design drug misuse experience hazard illicit opioid improved metropolitan mortality non-opioid analgesic novel opioid epidemic opioid injection opioid overdose opioid use disorder opioid withdrawal overdose risk prescription opioid prevent public health relevance public health research rate of change recidivism reduce symptoms response substance misuse treatment program

项目摘要

ABSTRACT TEXT In July of 2021, Rhode Island became the second state in the nation to decriminalize the possession of non-prescribed buprenorphine (NPB), the partial agonist opioid medication proven effective at treating opioid use disorder (OUD), following Vermont’s decriminalization of NPB the month prior. As the nation contends with the worst fatal overdose crisis in its history, and New York State considers decriminalizing NPB for 20 million residents, there is a time-sensitive need to understand the effects of this decriminalization on people’s consumption of buprenorphine both as part of formal treatment for OUD, and as self-treatment or a form of harm reduction. To date, however, no such evaluation has been conducted. Decriminalizing NPB is a novel response to the overdose crisis, based on evidence that most NPB consumption is for the purpose of self-treatment by people who do not have access to treatment, or do not perceive themselves as ready to succeed in formal treatment programs. It has also been associated with decreases in accidental overdose, and used as a form of protection from an adulterated illicit drug supply. At the same time, concerns among policymakers and legislators persist that consuming NPB unnecessarily delays participation in more comprehensive formal treatment, that when used in combination with non-opioid depressants it can contribute to overdose, and that it contributes to addiction when consumed recreationally, especially by opioid-naïve people. The goal of this project is to explore the effects of decriminalizing NPB on attitudes and beliefs toward buprenorphine in Rhode Island, and changes in buprenorphine’s association with fatal overdoses. It offers the opportunity to systematically examine how a change in the criminal law regulating a treatment medication affects attitudes and behaviors regarding it, allowing for a rapid and broad application of the findings. Using qualitative and quantitative measures, and closely harmonizing their efforts with researchers conducting a companion evaluation in Vermont, the research team will come to an understanding of 1) the knowledge, beliefs, and behaviors regarding decriminalized NPB of people who use illicit opioids; 2) the effects of decriminalized NPB on Rhode Island law enforcement practices, attitudes and beliefs, and 3) any post-decriminalization changes in buprenorphine’s association with fatal overdoses using data from Rhode Island’s State Unintentional Drug Overdose Reporting System. The results will yield both scientific publications and products for distribution to public administration and community stakeholder audiences. The study will produce an understanding of the effects of decriminalized NPB as New York and other states consider what role NPB decriminalization should play in their public health strategies, and will reveal the most insightful research questions and metrics for measuring the health and harm reduction outcomes of decriminalization in an ensuing R01 study.

抽象的文字